ABL Bio History
ABL Bio 가 걸어온 발자취를 소개합니다.
No. 1 Biotech in Korea
Became the leader among biotech firms in developing therapeutic drugs for immuno-oncology and neurodegenerative diseases using bispecific antibody.
Series C Funding (paid-in capital of 70 billion KRW, June)
Multiple contracts on bispecific antibody program and technology transfer
IPO on KOSDAQ, Dec. 19, 2018 (90 billion KRW of public offering)
Series B Funding (paid-in capital of 20 billion KRW, March)
ABL001 Clinical Trial Phase 1 (November)
ABL Bio Established (February)
Series A Funding (paid-in capital of 9 billion KRW, March)